A multi-institutional study of interlaboratory variance in the estrogen and progesterone receptor assays

Journal of Breast Cancer

Volumn 13, Issue 1, 2010, Pages 46-52

  Lee, Ahwon ^a   Gong, Gyungyub ^b   Park, Kyeongmee ^c   Park, In Ae ^d   Jung, Woo Hee ^e   Lee, Dong Wha ^f  

^a The Catholic University of Korea College of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Inje University College of Medicine   (South Korea)

^d Seoul National University College of Medicine   (South Korea)

^e Yonsei University College of Medicine   (South Korea)

^f Soonchunhyang University College of Medicine   (South Korea)

Author keywords

Immunohistochemistry; Key words: estrogen receptors; Progesterone receptors; Questionnaire

Indexed keywords

ESTROGEN RECEPTOR; FIXATIVE; FORMALDEHYDE; PROGESTERONE RECEPTOR; RECEPTOR ANTIBODY;

ARTICLE; AUTOCLAVE; BREAST CANCER; CONTROLLED STUDY; E-MAIL; HOSPITAL LABORATORY; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; KOREA; LABORATORY DIAGNOSIS; METHODOLOGY; MICROWAVE RADIATION; PROTEIN EXPRESSION; QUALITY CONTROL; QUESTIONNAIRE; STAINING; STANDARDIZATION; TUMOR CELL; VARIANCE;

EID: 77953209125     PISSN: 17386756     EISSN: None     Source Type: Journal    
DOI: 10.4048/jbc.2010.13.1.46     Document Type: Article

References (17)

1. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-81.
2. Greene GL, Nolan C, Engler JP, Pjensen EV. Monoclonal antibodies to human estrogen receptor. Proc Natl Acad Sci USA 1980;77:5115-9.
3. Greene GL, Jensen EV. Monoclonal antibodies as probes for estrogen receptor detection and characterization. J Steroid Biochem 1982;16: 353-9.
4. Alberts SR, Ingle JN, Roche PR, Cha SS, Wold LE, Farr GH Jr, et al. Comparison of estrogen receptor determinations by a biochemical ligand-binding assay and immunohistochemical staining with monoclonal antibody ER1D5 in females with lymph node positive breast carcinoma entered on two prospective clinical trials. Cancer 1996;78: 764-72.
5. Barnes DM, Harris WH, Smith P, Millis RR, Rubens RD. Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Br J Cancer 1996;74:1445-51.
6. Barnes DM, Millis RR, Beex LV, Thorpe SM, Leake RE. Increased use of immunohistochemistry for oestrogen receptor measurement in mammary carcinoma: the need for quality assurance. Eur J Cancer 1998;34:1677-82.
7. Rhodes A, Jasani B, Barnes DM, Bobrow LG, Miller KD. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol 2000;53:125-30.
8. Rhodes A, Jasani B, Balaton AJ, Barnes DM, Anderson E, Bobrow LG, et al. Study of interlaboratory reliability and reproducibility of estrogen and progesterone receptor assays in Europe. Am J Clin Pathol 2001;115:44-58.
9. Mann GB, Fahey VD, Feleppa F, Buchanan MR. Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer. J Clin Oncol 2005;23:5148-54.
10. Rudiger T, Hofler H, Kreipe HH, Nizze H, Pfeifer U, Stein H, et al. Quality assurance in immunohistochemistry: results of an interlaboratory trial involving 172 pathologists. Am J Surg Pathol 2002;26: 873-82.
11. Joo HJ. Quality control for immunohistochemistry. In: Committee for Quality Control of the Korean Society of Pathologists. Manual for Quality Control. Seoul: Designmecca; 2006. p.139-56.
12. Taylor CR. FDA issues final rule for classification and reclassification of immunohistochemistry reagents and kits. Am J Clin Pathol 1999; 111:443-4.
13. Rhodes A, Jasani B, Balaton AJ, Miller KD. Immunohitochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries. J Clin Pathol 2000;53:292 301.
14. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000; 124:966 78.
15. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann Bsenn HJ. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005;16:1569-83.
16. Umemura S, Kurosumi M, Moriya T, Oyama T, Arihiro K, Yamashita H, et al. Immunohistochemical evaluation for hormone receptors in breast cancer: a practically useful evaluation system and handling protocol. Breast Cancer 2006;13:232-5.
17. Yun YH, Park SM, Noh DY, Nam SJ, Ahn SH, Park BW, et al. Trends in breast cancer treatment in Korea and impact of compliance with consensus recommendations on survival. Breast Cancer Res Treat 2007;106:245-53.